大剂量联苯双酯抗乙型肝炎病毒疗效的临床观察

目的：探讨联苯双酯在治疗慢性乙型肝炎中的抗病毒作用。方法：119例患者随机分为治疗组和对照组,治疗组65例患者服用大剂量联苯双酯滴丸（≤12岁者剂量为30－45mg/d,＞12岁者剂量为45－67．5mg/d,持续用药时间至少12个月,同时选择使用复合氨基酸、维生素、熊去氧胆酸等护肝药物。 对照组54例患者,不用联苯双酯及含联苯双酯成份的制剂,其余药物与治疗组相同。治疗期间定期检测肝脏功能、血清HBeAg、HBeAb和HBV DNA。结果：治疗组的HBeAg、HBeAb和HBV DNA血清转换率明显高于对照组（P＜0．01）,治疗24个月后HBeAg和HBV DNA阴转率分别达到44．4％（24／54）和38．5％（25／65）,HBeAb阳转率达29．3％（17／58）。未见明显副反应。结论：大剂量长期服用联苯双酯具有明显的抗HBV作用。

Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B,a primary study

OBJECTIVE: To investigate the anti-HBV efficacy of bifendate in treatment of chronic hepatitis B. METHODS: A total of 119 patients with chronic hepatitis B were randomly divided into treatment group (n = 65, aged 24 +/- 12) and control group (n = 54, aged 25 +/- 11). In the treatment group every patient was given higher doses bifendate pills ( 12 age, 45 approximately 67.5 mg/d) for up to 12 months. Hepatic function test was performed and HBeAg, HBeAb and HBV DNA were detected at regular intervals in all patients. RESULTS: The serum alanine amonotransferase (ALT) decreased to normal only one month later in 70.76% of patients in the treatment group and decreased to normal at least in 2 approximately 3 months in the control group (P < 0.01). The serum conversion rates of HBeAg, HBeAb and HBV DNA in the treatment group were 44.4%, 29.3%, 38.5%, respectively, which were significantly higher than those in the control group (P < 0.01). No noticeable side effect was observed. CONCLUSION: Higher doses of bifendate taken for a long term has remarkable anti-HBV efficacy in treatment of chronic hepatitis B.